Full Press Release Details
CEO, Steven Lydeamore to host an investor webinar
Melbourne, Australia, February 15, 2023: Immuron
Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially
available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted
by Steven Lydeamore, CEO of Immuron Limited.
This release has been authorised by the directors of Immuron Limited.
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea,
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
Travelan is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with
meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers' diarrhea. In Australia,
Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce
the risk of Travelers' Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan
is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S.,
Travelan is sold as a dietary supplement for digestive tract protection.
About Travelers' diarrhea
is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,
and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with travelers' diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one
commercial asset generating revenue. In Australia, Travelan is a listed medicine on the Australian Register of Therapeutic Goods
(AUST L 106709) and is indicated to reduce the risk of Travellers' Diarrhea, reduce the risk of minor gastro-intestinal disorders
and is antimicrobial. In Canada, Travelan is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk
of Travellers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection in accordance
with section 403 (r)(6) of the Federal Drug Administration (FDA).
For more information
visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
press release may contain "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements
that are not historical facts. Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently anticipated include: risks
relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of
products under development; our need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as other risks described in
our SEC filings. We expressly disclaim any obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements contained herein to reflect any
change in our expectations or any changes in events, conditions or circumstances on which
any such statement is based, except as required by law.